POSIFLEX-TECHNOLOGY
15.3.2024 03:28:35 CET | Business Wire | Press release
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, is pleased to announce that its Haydn ZT Series - the industry's first clamshell POS terminal with a patented modular design and exceptional serviceability - and its Gen9 Base, which integrates a thermal printer and power supply for maximum space efficiency, have been awarded the iF DESIGN AWARD 2024 in the discipline of Product in the Public/Retail category by the Hannover-based iF International Forum Design GmbH, which is one of the most coveted accolades in the world of design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314845350/en/
Posiflex Wins the iF DESIGN AWARD 2024 for Haydn ZT Series and Gen9 Base (Graphic: Business Wire)
The Posiflex Haydn ZT Series and Gen9 Base stood out from a field of nearly 11,000 entries from 72 countries, impressing the 132-strong jury of independent experts from around the world with innovative designs and technical excellence aimed at delivering the highest levels of convenience and value to users and consumers.
Haydn ZT Series: The Industry's First Clamshell POS Terminal
The Posiflex Haydn ZT Series redefines the mechanical structure of POS terminals with the world's first clamshell design. This design simplifies maintenance tasks by allowing the monitor to be effortlessly lifted with just a slide of the hidden lever. It provides convenient access to internal modular components and facilitates easy and seamless repairs, replacements, and upgrades. Such innovation promises to significantly reduce downtime in case of a crash, minimizing inconvenience and financial losses associated with such incidents.
Gen9 Base: A Multi-Functional POS Terminal Base
The Gen9 Base is a multi-functional POS terminal base that integrates a built-in high-speed 250mm/second thermal receipt printer with auto-cutter concealed within its lightweight, screwless housing, in addition to hidden I/O, power and cabling designs, all of which combine to achieve a clean and stylish look and a clutter-free countertop. The POS terminal base also offers the option of a second monitor, expandable up to 15.6 inches, for maximum space efficiency and convenience for users and consumers.
Owen Chen, CEO of Posiflex Technology remarked, "Winning the iF DESIGN AWARD 2024 for our Haydn ZT Series and Gen9 Base is a testament to Posiflex's relentless pursuit of excellence in product design and innovation. Posiflex has been committed to pushing the boundaries of technological innovation to enhance the experiences of our customers worldwide.”
Being recognized by the esteemed iF International Forum Design GmbH reaffirms our position as a leader in the industry and motivates us to continue delivering cutting-edge solutions that meet the evolving needs of our customers. The Haydn ZT POS terminal series and Gen9 Base epitomize our dedication to innovation-driven entrepreneurship and unwavering focus on putting our customers first.
More information about The Haydn ZT Series and Gen9 Base can be found at: https://ifdesign.com/en/search?find=posiflex
About POSIFLEX Group
Posiflex Group is a leading global Commercial Internet of Things (CIoT) platform powered by smart Online-to-Offline (O2O) and Software-agnostic Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314845350/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom